Intramyocellular lipid kinetics and insulin resistance by Guo, ZengKui
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Review
Intramyocellular lipid kinetics and insulin resistance
ZengKui Guo*
Address: Endocrine Research Unit, Mayo Foundation, Rochester, Minnesota 55905, USA
Email: ZengKui Guo* - guo.zengkui@mayo.edu
* Corresponding author    
Abstract
More than fifteen years ago it was discovered that intramyocellular triglyceride (imcTG) content in
skeletal muscle is abnormally high in conditions of lipid oversupply (e.g. high fat feeding) and, later,
obesity, type 2 diabetes (T2D) and other metabolic conditions. This imcTG excess is robustly
associated with muscle insulin resistance (MIR). However, to date the pathways responsible for the
imcTG excess and the mechanisms underlying the imcTG-MIR correlation remain unclear. A
current hypothesis is based on a backward mechanism that impaired fatty acid oxidation by skeletal
muscle causes imcTG to accumulate. As such, imcTG excess is considered a marker but not a
player in MIR. However, recent results from kinetic studies indicated that imcTG pool in high fat-
induced obesity (HFO) model is kinetically dynamic. On one hand, imcTG synthesis is accelerated
and contributes to imcTG accumulation. On the other, the turnover of imcTG is also accelerated.
A hyperdynamic imcTG pool can impose dual adverse effects on glucose metabolism in skeletal
muscle. It increases the release and thus the availability of fatty acids in myocytes that may promote
fatty acid oxidation and suppress glucose utilization. Meanwhile, it releases abundant fatty acid
products (e.g. diacylglycerol, ceramides) that impair insulin actions via signal transduction, thereby
causing MIR. Thus, intramyocellular fatty acids and their products released from imcTG appear to
function as a link to MIR. Accordingly, a forward mechanism is proposed that explains the imcTG-
MIR correlation.
Background
Intramyocellular triglyceride (imcTG) is an important
energy source for skeletal muscle. In 1991, Storlien and
associates reported that under high fat feeding, imcTG
content is elevated to abnormally high levels and this is
correlated with muscle insulin resistance (r = 0.86–0.95)
[1]. The observation has been since confirmed in a
number of other models of insulin resistance such as
obesity, T2D and hypertension [2-7]. As skeletal muscle
accounts for the bulk of insulin-mediated glucose dis-
posal and thus is important for systemic energy metabo-
lism, the implication of this imcTG-MIR correlation to
health and disease is significant. This is exemplified by the
ensuing active investigations on this subject [3,8-11]. The
establishment and utilization of proton MRS technology
for in vivo measurement of imcTG content was largely in
response to these investigations [12-15]. However, most
of the investigations have been largely correlative in
nature.
Now it is increasingly realized that imcTG is the most
robust correlate of MIR, stronger than other metabolic
indicators such as % body fat, body mass index (BMI) and
waist-hip ratio [2]. This suggested a more substantive role
for imcTG in MIR, rather than merely a marker of MIR.
However, investigations on the mechanism(s) underlying
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the imcTG-MIR correlation have been less fruitful than the
studies of imcTG pool size so that it remains a phenome-
non not well understood as to whether and how the
enlarged imcTG pool is related to MIR. Glucose-fatty acid
cycling (i.e. Randle cycle) was considered by some to
explain, at least in part, the correlation due to the interac-
tions between glucose and fatty acid metabolism (sub-
strate competition) [16]. However, later the emphasis of
the investigations seems to have shifted to the area of sig-
nal transduction. It has been shown that under conditions
of lipid oversupply, obesity and other forms of insulin
resistance, the content of signaling molecules, including
long chain acyl CoA (LCACoA), diacylglycerol (DAG) and
ceramides are increased in skeletal muscle [9]. These mol-
ecules interfere with insulin signaling via PKC system,
thereby contributing to MIR [17-19]. Metabolic inflexibil-
ity theory has also been proposed to explain MIR in T2D
[20].
By comparison, there have been limited research efforts
on the kinetics of imcTG metabolism, and its role in MIR,
such as synthesis, turnover and oxidation, the pathways
that determine imcTG pool size. In the face of enlarged
imcTG pool size, abnormality in imcTG kinetics may
function as an independent factor to exert metabolic con-
sequences by altering intramyocellular fatty acid metabo-
lism, thereby contributing to MIR. This review is focused
on the synthesis, turnover and utilization of fatty acids
and their derivatives derived from the intramyocellular
neutral lipid pool (imcTG) and their roles in MIR as
related to obesity and T2D.
imcTG synthesis
For imcTG content to increase, its synthesis must increase
or its utilization decreases, or both. At present time, it is
not clear whether it is the synthetic or utilization limb(s)
that is responsible for the observed excess imcTG accumu-
lation. Clarifying this question is important, however. If it
is the utilization, then it would imply that imcTG excess is
merely a marker (consequence) of impaired fatty acid uti-
lization (β-oxidation). This is termed backward mecha-
nism, meaning that reduced fatty acid oxidation acts
backward to cause imcTG accumulation, the substrate
source pool for β-oxidation. In contrast, if it is the synthe-
sis, it would mean that imcTG is more actively involved as
a source of MIR by accumulating excess amount of fatty
acids in it. To maintain imcTG homeostasis, the enlarged
imcTG pool turns over rapidly and thus releases abundant
fatty acid products that interfere with insulin signaling.
This is termed forward mechanism, meaning that imcTG
is the source pool that causes the adverse consequences.
For the purpose of pharmaceutical intervention of MIR,
the two mechanisms mean different targets. The backward
mechanism requires manipulation (to stimulate) of fatty
acid utilization in order to normalize imcTG pool size and
to eliminate fatty acid products that impair insulin signal-
ing. In contrast, the forward mechanism requires modula-
tion (to suppress) of imcTG turnover or hydrolysis to
contain intracellular fatty acid flux and availability. There-
fore, it is important to determine which mechanism is
(more) responsible for MIR.
Toward this direction, we have observed that the rate of
incorporation of glycerol and fatty acid precursors into
imcTG (synthesis) is grossly accelerated in three muscle
types, gastrocnemius, soleus and tibialis anterior, in HFO
rats [21]. The rate of imcTG synthesis was 2 (soleus) to 5
(gastrocnemius) fold higher than in lean littermates after
3 months on a high fat diet (55% energy from lard) at age
of 4 months. At age of 8 months after 7 months on the
diet, the rate of imcTG synthesis further accelerated to 3
(soleus and gastrocnemius) to 5 (tibialis anterior) fold
higher in HFO rats. However, the accelerated imcTG syn-
thesis slowed down by age of 12 months and 11 months
on the same diet (~2 fold higher, soleus and gastrocne-
mius). In absolute term, the rate of imcTG synthesis is the
highest at age of 8 months (5 nmol glycerol incorporated/
g wet wt·min) and lowest at 12 months of age (<1 nmol/
g ww·min) while it is intermediate at 4 months (2–3
nmol/g·min). In all age groups, imcTG pool size was cor-
related with synthesis rate [21]. As supporting evidence, it
has been reported that in the heart of diabetic rats, TG syn-
thesis is also accelerated which contributes to imcTG
excess [22]. These are direct evidence that biosynthesis
plays a pivotal role in imcTG accumulation at least in this
obesity model. However, pool size was not always a func-
tion of synthesis, suggesting roles of other pathways, such
as imcTG turnover and fatty acid utilization (below).
Therefore, imcTG excess is a result of imbalance between
exaggerated influx (synthesis) and efflux (utilization) of
fatty acids into and out of the pool, respectively. On the
other hand, synthesis appears to play the leading role even
if fatty acid oxidation is increased, as reported. In other
words, increase in synthesis overruns increase in oxida-
tion, thereby resulting in net imcTG accrual. However,
this is not the case during aging. imcTG synthesis reaches
the plateau at around 8 months and then declines sub-
stantially at mid life (assuming a life span of 24 months).
This regression in synthetic activity coincides with
decreased lipid utilization and mitochondrial functions
[23] and is inversely related to aging-related increase in
imcTG stores [24]. Therefore, it seems that imcTG excess
is mainly a result of accelerated synthesis when young but
of decreased lipid utilization during aging.
The accelerated imcTG synthesis in HFO is consistent with
our observation that in these rats, >80%, compared to
50% in lean rats, of plasma palmitate traverses imcTG
before being oxidized in gastrocnemius. This indirect oxi-
dation of plasma fatty acids (by traversing imcTG poolLipids in Health and Disease 2007, 6:18 http://www.lipidworld.com/content/6/1/18
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first) may make imcTG synthesis falsely high when it is
determined based on substrate incorporation as we did.
This probably explains why imcTG pool size is not a pre-
cise function of its synthesis rate. This illustrates again the
point that imcTG pool size is determined by the delicate
balance between influx and efflux, but not by either alone.
Nonetheless, a conclusion that can be drawn from these
observations is that the kinetics of imcTG synthesis in the
HFO model is greatly accelerated and it likely plays an
important role in imcTG accumulation. So far, while
likely involved, the quantitative role of circulating VLDL-
TG fatty acids in imcTG synthesis has not been studied.
It is important to point out that the accelerated synthesis
in the HFO model was not a result of direct (high fat) die-
tary effects as plasma fatty acids, glycerol, triglycerides and
glucose were all experimentally matched between lean
and obese groups by substrate co-infusion [21]. Therefore,
acceleration in imcTG synthesis is a phenotypic character-
istic of obesity. This is in contrast with the assumption
that imcTG excess is a result of reduced fatty acid utiliza-
tion [25,26]. It is important to note that the assumption is
largely based on the activities of enzymes involved in lipid
oxidation such as CS (citrate synthase) and CPT1 (carni-
tine palmitoylacyltransferase-1), which are often discrep-
ant from actual substrate flux. In fact, a large body of
literature showed that lipid oxidation by skeletal muscle
in obesity is actually increased [27,28].
imcTG turnover
The study of imcTG turnover kinetics is very limited and
no such studies seem to have been reported in relation to
MIR. The limited reports indicated that in resting healthy
humans, imcTG pool turns over slowly with a fractional
rate of 0.0026/min (calculated from the reported rate, 29
h/pool) [29]. By using pulse (to prelabel imcTG pool with
14C-palmitate)-chase (to monitor the decay rate of the
incorporated tracer) technique, we have determined that
in young and healthy men and women exercising at 45%
of VO2max, the fractional turnover rate (FTR) of imcTG was
0.0032 ± 0.0007/min [30]. By comparison, as expected, in
rodents imcTG turns over much faster. In resting lean rats,
FTR of imcTG was determined to be 0.013 ± 0.005/min,
0.016 ± 0.005/min and 0.0072 ± 0.003%/min for gastroc-
nemius, tibialis anterior and soleus muscle, respectively.
In HFO rats, FTR of imcTG is even higher (0.026 ± 0.002/
min for gastrocnemius, P = 0.02 and 0.030 ± 0.002/min
for tibialis anterior, P = 0.01) compared to the values in
the lean [31]. However, the obesity-related acceleration in
imcTG turnover was not observed for soleus muscle, per-
haps reflecting its larger pool size and thus lower FTR.
These findings are in contrast to the view that in obesity
and T2D imcTG is a static pool turning over slowly that
contributes to its excess accumulation [25]. The data
reported for HFO rats indicated that it is clear that imcTG
pool is not only enlarged but also kinetically hyperdy-
namic, meaning that its synthesis and turnover are both
accelerated as compared to lean control. As turnover is a
reflection of 2 opposing pathways, synthesis and lipolysis,
the data suggested that these pathways are both acceler-
ated several folds in HFO. This implies that imcTG recy-
cles rapidly (imcTG → fatty acids → acyl CoA → imcTG).
In humans, imcTG recycles constantly at least during exer-
cises [30].
The accelerated imcTG dynamics, compounded by its
enlarged pool size, translates into remarkable increases in
the release of fatty acids from it. This results in increased
fatty acid trafficking and availability in myocytes. Indeed,
we routinely observed increases in intramyocellular non-
esterified fatty acids (NEFA) in the HFO rats compared to
lean control (gastrocnemius by 70%, soleus by 89% and
extensor digitorus longus by 106%, all P < 0.01). Under
the action of acyl CoA synthase, long chain fatty acids are
rapidly activated to long chain acyl CoA. They are precur-
sors to several pathways including mitochondrial β-oxida-
tion and signal transduction.
imcTG-fatty acid oxidation
An immediate fate for long chain acyl CoA is β-oxidation
in mitochondria after being converted to long chain acyl-
carnitines catalyzed by CPT1 (the required form of long,
but not medium or short, chain fatty acids to enter mito-
chondria). Peroxisomal β-oxidation is minor as the path-
way primarily functions to shorten very long fatty acids for
further oxidation by mitochondria [32,33]. Theoretically,
by mass action alone, increased fatty acids may accelerate
the cascade and thus mitochondrial β-oxidation. The
close vicinity between imcTG droplets and mitochondria
in myocytes [34] further facilitates this process. In fact,
this is supported by experimental evidence. It has been
extensively reported that lipid oxidation in obesity and
T2D is increased [35,36]. Our preliminary results from in
vivo studies in HFO rats confirmed this (unpublished
data). Fatty acid oxidation is known to interfere with glu-
cose metabolism through substrate competition [37], a
well established mechanism under certain metabolic con-
ditions substantiated by a large body of literature
[27,28,38,39]. Therefore, a hyperdynamic imcTG pool
can interfere with glucose metabolism at substrate level
independently. The role of signal transduction, involving
diacylglycerol and ceramides and perhaps long chain acyl
CoA, via the PKC/IRS-1/PIK3 axis, in MIR can presumably
supplement, but not substitute, this possibility. For exam-
ple, substrate competition and signaling transduction
may operate simultaneously. There are no reports whether
they antagonize or are exclusive to each other. Experi-
ments designed to test this hypothesis would be interest-Lipids in Health and Disease 2007, 6:18 http://www.lipidworld.com/content/6/1/18
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ing and important for understanding of the interactions
between signaling and β-oxidation pathways.
imcTG-fatty acid signaling
NEFA and their derivatives (acyl CoA, diacylglycerol and
ceramides) are also signaling molecules. Therefore,
increased intramyocellular fatty acid availability may exert
additional effects on muscle metabolism via signal trans-
duction. Now it is known that the content of these mole-
cules in skeletal muscle is increased with lipid oversupply
and in obesity [17]. They activate PKCα,θ,ε isoforms
which in turn phosphorylates serine/threonine residues of
insulin receptor (IR) and insulin receptor substrate-1
(IRS-1) [9,17]. This in turn inhibits the activation of IR
and IRS-1 (tyrosine phosphorylation), thereby impairing
insulin signaling with retarded GLUT4 translocation to
the plasma membrane compartment and hence reduced
insulin-mediated glucose uptake (MIR).
The turnover of imcTG releases 1,2-diacylglycerol [40]
and other isomers (1,3- and 2,3-). One diacylglycerol and
one acyl CoA molecule (catalyzed by acyl CoA synthase)
are produced from the hydrolysis of each imcTG mole-
cule. The combined effects of these molecules may be
powerful in inhibiting insulin signaling. We have
observed that in HFO rats, the content of diacylglycerol in
gastrocnemius, soleus and extensor digitorus longus is
52% (P < 0.01), 37% (P < 0.05) and 88% (P < 0.01)
higher than in lean control, and is positively correlated
with imcTG pool size and imcTG turnover rate. These
observations suggest a precursor-product relationship
between imcTG and diacylglycerol. Furthermore, imcTG
as a source of these molecules has been confirmed using
tracer techniques. Using 14C-glycerol, increased produc-
tion of diacylglycerol from imcTG in gastrocnemius and
soleus muscles of HFO rats has been observed compared
to lean control. Therefore, an enlarged pool size and accel-
erated turnover of imcTG perhaps act in concert to
increase the production of signaling molecules.
While diacylglycerol is a classical second messenger,
whether the thioester form (acyl CoA) or the free form of
fatty acids is the active form for signaling seems unclear.
Contrasting to many other reports, Forman et al reported
that the carboxyl group, -COOH, is required for the sign-
aling activity and upon thioesterification, the activity is
lost [41]. Nonetheless, as the two forms can interchange
readily through enzymatic actions, this may not be a crit-
ical issue regarding the role of fatty acid signaling in MIR.
Although elevated long chain acyl CoA and diacylglycerol
in conditions of lipid oversupply and insulin resistance
have been extensively reported [17,19,42,43], the roles of
imcTG turnover in this process have not been directly
studied. Clarifying this question is important. If rapid
imcTG turnover increases the production and the content
of these signaling molecules, then it can be concluded that
imcTG turnover kinetics contributes to MIR. In other
words, rapid turnover functions as a link between imcTG
and MIR. If so, imcTG is a source, not only a marker, of
MIR. Therefore, turnover pathway of imcTG (e.g. hydroly-
sis) can be used as a target for the intervention of MIR by
manipulating intracellular fatty acid dynamics and availa-
bility. Studies designed to quantify the flux of signaling
molecules from imcTG pool may provide the needed
information for pursuing in this direction.
Fatty acids are also precursor to ceramides, yet another
member of the same signaling molecule family with sim-
ilar functions. Thus, increased fatty acid availability can
promote ceramide synthesis, further impairing insulin
signaling.
Collectively, long chain acyl CoA, diacylglycerol and cera-
mides can all be produced from imcTG. When imcTG
pool becomes enlarged, the fluxes are increased. Hyperdy-
namic turnover amplifies and worsens this mass effect. As
a result, excess amounts of signaling molecules are pro-
duced that activate PKC isoforms and inactivate PI3
kinase, thereby resulting in MIR (Fig 1).
Given the clear evidence of inhibitory effects of these mol-
ecules on insulin signaling, conceptually reduced fatty
acid oxidation can further worsens glucose metabolism
when more fatty acids become available for signaling.
However, this may not necessarily be the case in that
increased fatty acid oxidation may not be able to effec-
tively divert fatty acids away from signaling pathways
because of the great availability of fatty acids released
from imcTG that may suffice for both pathways. In such
case, glucose metabolism is subject to dual suppressions.
On one hand, insulin-mediated glucose uptake is attenu-
ated as a result of impaired insulin signaling (e.g. post-
prandial). On the other hand, glucose uptake is reduced
via substrate competition due to increased fatty acid oxi-
dation (e.g. postabsorptive). This may be the case when
muscle lipid oxidation in obesity and type 2 diabetes is
elevated [27,28,44,45]. However, to accept this scenario
requires direct demonstration that both fatty acid oxida-
tion and the signaling pathways are active. Nonetheless, it
is clear that obesity is associated with a cluster of imcTG
abnormalities including enlarged pool size, accelerated
turnover, increased oxidation and production of fatty
acids and their derivatives as signaling molecules. The
metabolic effects of this cluster appear to link imcTG to
MIR. This supports a forward mechanism where imcTG is
a source of MIR. However, the mechanism may operate in
overweight or non-severe obesity where lipid oxidation by
muscle is likely high, but perhaps not in severe obesity
where muscle lipid oxidation is low [8]. In severe obesityLipids in Health and Disease 2007, 6:18 http://www.lipidworld.com/content/6/1/18
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and during aging, the backward mechanism likely domi-
nates.
imcTG kinetics and MIR in humans
Studies of imcTG kinetics in humans are rare and virtually
lacking as related to obesity, T2D or other metabolic dis-
eases. Limited data are only available for healthy humans
where imcTG turns over at 0.26%/min at rest [29] and
0.32%/min during modest exercises [30]. Therefore, it is
not clear currently whether the forward mechanism is rel-
evant in human obesity. Clearly, investigations on imcTG
kinetics as related to MIR are required. On the other hand,
based on the extensive reports on increased lipid oxida-
tion by skeletal muscle in obesity and perhaps to a lesser
extent in T2D, it is reasonable to estimate that the turno-
ver of intramyocellular fatty acids, mainly of imcTG ori-
gin, is perhaps also accelerated as it is a prerequisite for
increased oxidation (permissive role). For example,
increases in oxidation are impossible without increase in
fatty acid release from imcTG. Indeed, turnover and oxida-
tion are often quantitatively related [46,47].
Overall, animal studies on imcTG kinetics are limited as
well. By comparison, studies on heart triglyceride kinetics
have been more active. Similar to that observed for HFO
rats, heart triglyceride synthesis and turnover and fatty
acid oxidation are all accelerated in diabetic rats
[22,48,49]. Therefore, it appears that both obesity and
diabetes are associated with hyperdynamics of intracellu-
lar triglyceride metabolism which likely contributes to
MIR and cardiomyopathy. This supports the forward
mechanism.
Aging and MIR
As discussed above, in middle-aged HFO rats imcTG syn-
thesis remains accelerated but attenuation was apparent
compared to younger age. This pattern of changes in
imcTG synthesis is consistent with the known aging-
related functional regressions of mitochondria in
humans, such as declines in biogenesis, oxidative capacity
and oxidation-phosphorylation [50,51]. As a result, mito-
chondrial  β-oxidation is reduced [23,52]. To maintain
metabolic homeostasis, this is counter-balanced by reduc-
tion in imcTG synthesis. However, imcTG may continue
to accumulate in excess [51] as a result of imbalance (i.e.
reduction in utilization overruns reduction in synthesis).
In this sense, imcTG excess is a random event as indicated
by the fact that imcTG is not always increased in all insu-
lin resistant states. This scenario confers with the back-
ward mechanism where impaired lipid utilization causes
imcTG to accumulate [23]. The mechanism seems also rel-
evant to T2D which is associated with mitochondrial dys-
function along with MIR and imcTG excess [50]. This
hypothesis seems more plausible considering that T2D
develops more likely with aging and at the late stage of
insulin resistance associated with obesity. Thus, in T2D as
well as in aging, imcTG excess is a result, rather than
source, of MIR.
However, the backward mechanism does not appear to
explain imcTG excess for other types of insulin resistance
such as simple (non-diabetic) and non-severe obesity.
Rather, the forward mechanism is more relevant to obes-
ity at relatively young ages where insulin resistance is rel-
atively mild without apparent alterations in
mitochondrial structure, morphology or functions as seen
in severe obesity, T2D or advanced aging. Indeed, patho-
logical changes in subsarcolemmal mitochondria is more
advanced in T2D than in obesity [53]. Instead, imcTG
hyperdynamics is the predominant abnormality in obes-
ity at early stage or younger ages associated mainly with
signaling via PKC/PI3K systems and/or increased mito-
chondrial  β-oxidation. These conditions perturb (over-
load) mitochondrial functions via mechanisms such as
oxidative stress and inflammation. From these abnormal-
ities, mitochondrial dysfunctions and structural altera-
tions can gradually develop (e.g. mtDNA damages, ref.
[54]). As this process continues, accompanied by aging,
the forward mechanism reverts to backward where mito-
Hydrolysis of imcTG produces DAG and LCACoA which is  also precursor to ceramides Figure 1
Hydrolysis of imcTG produces DAG and LCACoA which is 
also precursor to ceramides. All three can activate PKC iso-
forms that inhibit insulin signaling. An enlarged and rapidly 
turning over imcTG pool increases the release of these fatty 
acid derivatives, thus causing MIR. Simultaneously, mitochon-
drial β-oxidation may increase given the large fatty acid flux 
thereby worsening MIR. FFA, (plasma) free fatty acids; LCFA, 
long chain fatty acids; LCACoA, long chain acyl CoA; LCAC, 
long chain acylcarnitines; PL, phospholipids; DAG, diacylglyc-
erol; PKC, protein kinase C; β, mitochondrial β-oxidation.Lipids in Health and Disease 2007, 6:18 http://www.lipidworld.com/content/6/1/18
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chondrial dysfunctions limit β-oxidation causing imcTG
to accumulate. Therefore, the forward mechanism under-
lies insulin resistance at earlier stages of obesity whereas
the backward mechanism prevails at later stages of insulin
resistance such as T2D and advanced aging (Fig 2).
New developments
The research on MIR evolves rapidly and some intriguing
observations have been reported recently. Increasing
imcTG pool size purposely by stimulating synthesis via
genetic manipulation surprisingly improved insulin sensi-
tivity and prevented high fat-induced insulin resistance
[55]. This echoes a previous report that promoting fatty
acid incorporation into imcTG reduced lipid toxicity in
myocytes [56]. These findings appear to suggest that elim-
inating/reducing fatty acid products in myocytes prevents
lipotoxicity and improves insulin sensitivity. This is com-
plementary to the observation that promoting fatty acid
oxidation reduced fatty acid products in skeletal muscle
and improved insulin sensitivity [18]. Promoting imcTG
synthesis also improved insulin sensitivity by protecting
against inflammation [57]. Collectively, these studies
essentially demonstrated that clearing up fatty acid prod-
ucts in myocytes using different approaches (e.g. pooling
into imcTG or eliminating via oxidation) has the same
effect of protecting cells against adverse effects. This is
consistent with the fact that provision of fatty acids
through plasma, which drastically increases intramyocel-
lular fatty acid levels, rapidly induces MIR (within hours).
Therefore, it appears that fatty acids and their derivatives
Schematic representation of forward (solid arrows) and backward (broken arrows) mechanism underlying MIR, as discussed Figure 2
Schematic representation of forward (solid arrows) and backward (broken arrows) mechanism underlying MIR, as discussed. 
By the forward mechanism, imcTG is at a hyperdynamic state characterized by accelerated synthesis (Syn, ref. 21) and turnover 
(TO, ref. 31) in the earlier stages of metabolic complications such as obesity. This increases the flux and availability of intramy-
ocellular fatty acids (FA/LCFA), DAG, LCACoA and ceramides and thus signaling via PKC system, and promotes mitochondrial 
β-oxidation (β). As a result, PI3K is inhibited and GLUT4 translocation impaired resulting in reduced insulin-mediated glucose 
uptake (MIR). Over time, the overloading of mitochondria by β-oxidation gradually causes mitochondrial damages and dysfunc-
tions (MD) via mechanisms such as oxidative stress and DNA damage. When this occurs, mitochondrial β-oxidation reduces. 
At this stage (e.g. T2D or advanced aging), the backward mechanism prevails. The decline in fatty acid oxidation causes imcTG 
to accumulate. Gray-scaled mitochondria (mito) represents damaged mitochondria. The thickness of arrows approximates the 
sizes of the fluxes.Lipids in Health and Disease 2007, 6:18 http://www.lipidworld.com/content/6/1/18
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that exist in intracellular compartments other than imcTG
are a source of lipotoxicity and MIR and thus 'eliminating'
them improves or protects insulin sensitivity.
Summary
Recent findings suggested that intramyocellular triglycer-
ide excess is a source, not only a marker, of muscle insulin
resistance. The hyperdynamic turnover kinetics and
enlarged pool size of imcTG function to release abundant
fatty acids and their products known to interfere with
insulin signaling and glucose metabolism via signal trans-
duction and/or substrate competition. As such, imcTG
hyperdynamics appears to be a link to MIR, as described
by a forward mechanism. Alternatively, muscle insulin
resistance and mitochondrial dysfunction in advanced
obesity, T2D and aging may reverse the course causing
imcTG to accumulate, as represented by a backward
mechanism. Clarifying the mechanisms has implications
to the understanding and potential intervention of muscle
insulin resistance. For example, with the forward mecha-
nism, the intramyocellular triglyceride pool is the target
whereas it is only a surrogate with the backward mecha-
nism.
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